These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31850981)

  • 21. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?
    Reeh M; Nentwich MF; Asani S; Uzunoglu FG; Bockhorn M; Sauter G; Rösch T; Izbicki JR; Bogoevski D
    J Gastrointest Surg; 2015 Apr; 19(4):587-93. PubMed ID: 25652343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
    Rice TW; Ishwaran H; Kelsen DP; Hofstetter WL; Apperson-Hansen C; Blackstone EH;
    Dis Esophagus; 2016 Nov; 29(8):906-912. PubMed ID: 27905170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.
    Brinkmann S; Noordman BJ; Hölscher AH; Biermann K; van Klaveren D; Bollschweiler E; Pütz K; van Lanschot JJB; Drebber U
    Ann Surg Oncol; 2020 Apr; 27(4):1250-1258. PubMed ID: 31691114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.
    Koen Talsma A; Shapiro J; Looman CW; van Hagen P; Steyerberg EW; van der Gaast A; van Berge Henegouwen MI; Wijnhoven BP; van Lanschot JJ; ; Hulshof MC; van Laarhoven HW; Nieuwenhuijzen GA; Hospers GA; Bonenkamp JJ; Cuesta MA; Blaisse RJ; Busch OR; ten Kate FJ; Creemers GJ; Punt CJ; Plukker JT; Verheul HM; van Dekken H; van der Sangen MJ; Rozema T; Biermann K; Beukema JC; Piet AH; van Rij CM; Reinders JG; Tilanus HW
    Ann Surg; 2014 Nov; 260(5):786-92; discussion 792-3. PubMed ID: 25379850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited resection for early adenocarcinoma in Barrett's esophagus.
    Stein HJ; Feith M; Mueller J; Werner M; Siewert JR
    Ann Surg; 2000 Dec; 232(6):733-42. PubMed ID: 11088068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.
    Barbour AP; Rizk NP; Gonen M; Tang L; Bains MS; Rusch VW; Coit DG; Brennan MF
    Ann Surg; 2007 Jul; 246(1):1-8. PubMed ID: 17592282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
    Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
    J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimum lymphadenectomy for esophageal cancer.
    Rizk NP; Ishwaran H; Rice TW; Chen LQ; Schipper PH; Kesler KA; Law S; Lerut TE; Reed CE; Salo JA; Scott WJ; Hofstetter WL; Watson TJ; Allen MS; Rusch VW; Blackstone EH
    Ann Surg; 2010 Jan; 251(1):46-50. PubMed ID: 20032718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
    Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
    Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Depypere L; De Hertogh G; Moons J; Provoost AL; Lerut T; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Ann Thorac Surg; 2021 Dec; 112(6):1847-1854. PubMed ID: 33352178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma.
    Lee IS; Ahn JY; Yook JH; Kim BS
    World J Surg Oncol; 2017 Jan; 15(1):28. PubMed ID: 28100248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma.
    McKay SC; Louie BE; Molena D; Andrews WG; Boerner T; Hofstetter WL; Yeung J; Darling GE; Sharata A; Peyre CG; Dunn C; Lipham JC; Marginean H; DeMeester SR
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1943-1950. PubMed ID: 37788788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer.
    Ruol A; Portale G; Castoro C; Merigliano S; Cagol M; Cavallin F; Chiarion Sileni V; Corti L; Rampado S; Costantini M; Ancona E
    Ann Surg Oncol; 2007 Nov; 14(11):3243-50. PubMed ID: 17713823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer.
    Vallböhmer D; Hölscher AH; DeMeester S; DeMeester T; Salo J; Peters J; Lerut T; Swisher SG; Schröder W; Bollschweiler E; Hofstetter W
    Ann Surg; 2010 Nov; 252(5):744-9. PubMed ID: 21037429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.